Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Axelrod ML, Cook RS, Johnson DB, Balko JM
Clin Cancer Res. 2019 25 (8): 2392-2402

PMID: 30463850 · PMCID: PMC6467754 · DOI:10.1158/1078-0432.CCR-18-3200

Immunotherapy has emerged as a key pillar of cancer treatment. To build upon the recent successes of immunotherapy, intense research efforts are aimed at a molecular understanding of antitumor immune responses, identification of biomarkers of immunotherapy response and resistance, and novel strategies to circumvent resistance. These studies are revealing new insight into the intricacies of tumor cell recognition by the immune system, in large part through MHCs. Although tumor cells widely express MHC-I, a subset of tumors originating from a variety of tissues also express MHC-II, an antigen-presenting complex traditionally associated with professional antigen-presenting cells. MHC-II is critical for antigen presentation to CD4 T lymphocytes, whose role in antitumor immunity is becoming increasingly appreciated. Accumulating evidence demonstrates that tumor-specific MHC-II associates with favorable outcomes in patients with cancer, including those treated with immunotherapies, and with tumor rejection in murine models. Herein, we will review current research regarding tumor-enriched MHC-II expression and regulation in a range of human tumors and murine models, and the possible therapeutic applications of tumor-specific MHC-II.

©2018 American Association for Cancer Research.

MeSH Terms (16)

Animals Antigen-Presenting Cells Antigen Presentation Biomarkers CD4-Positive T-Lymphocytes Disease Management Disease Models, Animal Disease Susceptibility Gene Expression Gene Expression Regulation, Neoplastic Histocompatibility Antigens Class I Histocompatibility Antigens Class II Humans Immunotherapy Neoplasms Signal Transduction

Connections (1)

This publication is referenced by other Labnodes entities:

Links